Journal of Reconstructive Urology

.: ORIGINAL RESEARCH
Sistemik İnflamatuar Belirteçlerin Post-Kemoterapi Retroperitoneal Rezidü Kitle Patolojisini Tahmin Etmedeki Rolü: Retrospektif Klinik Çalışma
The Role of Systemic Inflammatory Markers in Predicting Post-Chemotherapy Retroperitoneal Residual Mass Pathology: Retrospective Clinical Study
Abdullah GÜLa, Özgür EKİCİb, Salim ZENGİNa, Sinan AVCIc
aSağlık Bilimleri Üniversitesi Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Bursa, Türkiye
bNusaybin Devlet Hastanesi, Üroloji Kliniği, Mardin, Türkiye
cBursa Şehir Hastanesi, Üroloji Kliniği, Bursa, Türkiye
J Reconstr Urol. 2022;12(2):64-9
doi: 10.5336/urology.2022-89329
Article Language: TR
Full Text
ÖZET
Amaç: Kemoterapi sonrası retroperitoneal lenf nodu diseksiyonu (RPLND) uygulanan metastatik seminom dışı germ hücreli testis tümörü (NSGCT) hastalarında, preoperatif inflamasyon belirteçleri (nötrofil/lenfosit oranı (NLR), platelet/lenfosit oranı (PLR)) ve görüntüleme bulgularının RPLND patolojisi ile ilişkili olup olmadığını araştırmaktır. Gereç ve Yöntemler: Kliniğimizde Ocak 2016-Şubat 2022 tarihleri arasında RPLND yapılmış hastalar geriye dönük tarandı. Preoperatif hematolojik ve biyokimyasal parametreler, bilgisayarlı tomografi (BT) bulguları, orşiektomi ve RPLND histopatoloji bulguları kaydedildi. Hastalar patolojisi canlı tümör/teratom olanlar Grup 1 ve benign (nekroz-fibroz) olanlar Grup 2 şeklinde ayrıldı. Gruplar arasında NLR, PLR, De Ritis oranı, serum tümör belirteçleri ve abdominopelvik BT'de saptanan ek büyük boyuttaki retroperitoneal lenf nodunun uzunluğu, hem orşiektomi öncesi, hem kemoterapi öncesi, hem de RPLND öncesi dönemlerde karşılaştırıldı. Bulgular: Toplamda13 hasta çalışmaya dahil edildi (Grup 1: 10 hasta, Grup 2: 3 hasta). Gruplar arasında yaş ortalaması benzerken, orşiektomi öncesi hematolojik ve serum belirteçleri açısından fark saptanmadı (p>0,05). Kemoterapi öncesi hematolojik ve serum belirteçleri 2 grupta da benzerken, abdominopelvik BT'deki en büyük lenfadenopati (LAP) boyutları Grup 1'de anlamlı düzeyde yüksekti (p=0,03). Benzer şekilde RPLND öncesi hematolojik ve serum belirteçleri 2 grupta da benzerken, abdominopelvik BT'deki en büyük LAP boyutları Grup 1'de anlamlı düzeyde yüksekti (p=0.03). Sonuç: RPLND tümör histolojisinin preoperatif öngörüsünde basit kan testlerinin kullanımı pratik gibi gözükse de, bu tahmin için henüz tümör boyutundan başka anlamlı parametre bulunamamıştır.

Anahtar Kelimeler: Nötrofil lenfosit oranı; platelet lenfosit oranı; De Ritis oranı; retroperitoneal tümörler; testis tümörleri
ABSTRACT
Objective: To investigate whether preoperative inflammation markers (NLR, PLR) and imaging findings are associated with retroperitoneal lymph node dissection (RPLND) pathology in patients with metastatic non-seminomatous germ cell testicular tumor (NSGCT) who underwent RPLND after chemotherapy. Material and Methods: The data of the patients who underwent RPLND in our clinic between January 2016 and February 2022 were retrospectively analyzed. Preoperative hematological and biochemical parameters, computed tomography (CT) findings, orchiectomy and RPLND histopathology findings were recorded. The patients were divided into 2 groups according to RPLND pathology: Group 1 as viable tumor/teratoma and Group 2 as benign (necrosis-fibrosis) pathology. NLR, PLR, De Ritis ratio, serum tumor markers, and the length of the additional largest retroperitoneal lymph node detected on abdominopelvic CT between the groups were compared in the pre-orchiectomy, pre-chemotherapy and pre-RPLND periods. Results: A total of 13 patients were included in the study (Group 1: 10 patients and Group 2: 3 patients). While the mean age was similar between the groups, there was no difference in terms of hematological and serum markers before orchiectomy (p>0.05). While pre-chemotherapy hematological and serum markers were similar in both groups, the largest lymphadenopathy (LAP) sizes at abdominopelvic CT were significantly higher in Group 1 (p=0.03). Likewise, pre-RPLND hematological and inflammation markers were similar in both groups, while the largest LAP sizes at abdominopelvic CT were significantly higher in Group 1 (p=0.03). Conclusion: Although the use of blood test samples for preoperatively prediction of RPLND tumor histology seems practical, no significant parameter other than tumor size has yet been found.

Keywords: Neutrophil lymphocyte ratio; platelet lymphocyte ratio; De Ritis ratio; retroperitoneal neoplasms; testicular neoplasms
REFERENCES:
  1. Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore). 2018;97(37): e12390. [Crossref]  [PubMed]  [PMC] 
  2. Oldenburg J, Berney DM, Bokemeyer C, Climent MA, Daugaard G, Gietema JA, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org; EURACAN. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(4):362-75. [Crossref]  [PubMed] 
  3. Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94(6):1668-76. [Crossref]  [PubMed] 
  4. Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol. 2007;25(35):5603-8. [Crossref]  [PubMed] 
  5. Templeton AJ, McNamara MG, ?eruga B, Vera-Badillo FE, Aneja P, Oca-a A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. [Crossref]  [PubMed] 
  6. Gokcen K, Dundar G, Gulbahar H, Gokce G, Gultekin EY. Can routine peripheral blood counts like neutrophil-to-lymphocyte ratio be beneficial in prediagnosis of testicular cancer and its stages? J Res Med Sci. 2018;23:64. [Crossref]  [PubMed]  [PMC] 
  7. Ribnikar D, Stukalin I, Bedard PL, Hamilton RJ, Jewett M, Warde P, et al. The prognostic value of neutrophil-to-lymphocyte ratio in metastatic testicular cancer. Curr Oncol. 2020;28(1):107-14. [Crossref]  [PubMed]  [PMC] 
  8. Arıman A, Merder E. The prognostic importance of neutrophil-to-lymphocyte ratio in testicular cancer. Urologia. 2021;88(3):200-5. [Crossref]  [PubMed] 
  9. Gorgel SN, Akin Y, Koc EM, Kose O, Ozcan S, Yilmaz Y. Impact of increased aspartate aminotransferase to alanine aminotransferase (De Ritis) ratio in prognosis of testicular cancer. Investig Clin Urol. 2019;60(3):169-75. [Crossref]  [PubMed]  [PMC] 
  10. Guner E, Seker KG, Arikan Y, Huseynov C, Sam E, Ozdal OL. The utility of De Ritis Ratio in predicting prognosis in testicular cancer. Aktuelle Urol. 2020;51(3):285-9. [Crossref]  [PubMed] 
  11. Heidenreich A, Pfister D, Witthuhn R, Thüer D, Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol. 2009;55(1):217-24. [Crossref]  [PubMed] 
  12. Can C. Complications of surgical treatment in testicular cancers. Bulletin of Urooncology. 2008;3. [Link] 
  13. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-44. [Crossref]  [PubMed] 
  14. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002;60(1):78-83. [Crossref]  [PubMed] 
  15. Lin XC, Gao X, Lu GS, Song B, Zhang QH. Role of calcifying nanoparticles in the development of testicular microlithiasis in vivo. BMC Urol. 2017;17(1):99. [Crossref]  [PubMed]  [PMC] 
  16. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev. 2010;20(1):65-71. [Crossref]  [PubMed]  [PMC] 
  17. Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur Urol. 2021;79(1):62-79. [Crossref]  [PubMed] 
  18. Yuksel OH, Verit A, Sahin A, Urkmez A, Uruc F. White blood cell counts and neutrophil to lymphocyte ratio in the diagnosis of testicular cancer: a simple secondary serum tumor marker. Int Braz J Urol. 2016;42(1):53-9. [Crossref]  [PubMed]  [PMC] 
  19. Tan YG, Sia J, Huang HH, Lau WKO. Neutrophil-to-lymphocyte ratio independently predicts advanced pathological staging and poorer survival outcomes in testicular cancer. Investig Clin Urol. 2019;60(3):176-83. [Crossref]  [PubMed]  [PMC] 
  20. Şahin A, Toprak T, Kutluhan MA, Vural Y, Ürkmez A, Verit A. Increased neutrophil/lymphocyte ratio in testicular cancer. Arch Ital Urol Androl. 2019;91(2). [Crossref]  [PubMed] 
  21. Ilktac A, Dogan B, Ersoz C, Akcay M, Akbulut H. The relationship of neutrophil to lymphocyte ratio with testicular cancer. Int Braz J Urol. 2020;46(1):101-7. [Crossref]  [PubMed]  [PMC] 
  22. Bauzá Quetglas JL, Tienza Fernández A, Bertolo R, Sabaté Arroyo XA, Guimerà García J, Tubau Vida-a V, et al. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with testicular cancer. Prog Urol. 2020;30(5):273-80. [Crossref]  [PubMed] 
  23. Bolat D, Aydoğdu Ö, Polat S, Yarımoğlu S, Bozkurt İH, Yonguç T, et al. Predictive value of preoperative neutrophil-to-lymphocyte ratio on the prognosis of germ cell testicular tumors. Turk J Urol. 2017;43(1):55-61. [Crossref]  [PubMed]  [PMC] 
  24. Fankhauser CD, Sander S, Roth L, Gross O, Eberli D, Sulser T, et al. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy. Br J Cancer. 2018;118(6):825-30. [Crossref]  [PubMed]  [PMC] 
  25. De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957;2(1):70-4. [Crossref]  [PubMed] 
  26. Su S, Liu L, Li C, Zhang J, Li S. Prognostic role of pretreatment de ritis ratio (aspartate transaminase/alanine transaminase ratio) in urological cancers: a systematic review and meta-analysis. Front Oncol. 2020;10:1650. [Crossref]  [PubMed]  [PMC] 
  27. Olcucu MT, Karamik K, Yilmaz K, Okuducu Y, Cakir S, Ates M. Preoperative inflammation markers and de ritis ratio in predicting clinical presentation and prognosis of patients with testicular germ cell tumors. J Coll Physicians Surg Pak. 2020;30(10):1041-6. [Crossref]  [PubMed] 
  28. Winter C, Pfister D, Busch J, Bingöl C, Ranft U, Schrader M, et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol. 2012;61(2):403-9. [Crossref]  [PubMed] 
  29. Vergouwe Y, Steyerberg EW, Foster RS, Sleijfer DT, Fosså SD, Gerl A, det al. Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. Eur Urol. 2007;51(2):424-32. [Crossref]  [PubMed] 
  30. Leão R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, et al. A new model to predict benign histology in residual retroperitoneal masses after chemotherapy in nonseminoma. Eur Urol Focus. 2018;4(6):995-1001. [Crossref]  [PubMed] 

.: Up To Date

.: Process List

Login



Contact


Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com